Scope of US Patent 7,879,828 (tigecycline-lactose acidified compositions): claim boundaries, fallback positions, and US patent landscape
US Drug Patent 7,879,828 claims a narrow excipient-and-buffer-controlled composition: tigecycline + lactose + a specified acid (HCl or gentisic acid), with explicit molar ratio and explicit solution pH windows, including solid/lyophilized embodiments and tighter subranges for ratio and pH.
Because the provided material includes only the asserted claim set and not (i) the patent specification, (ii) the prosecution history, or (iii) any Orange Book or litigation record, the analysis below is limited to what can be derived from the claim language itself: scope, claim construction levers, design-around vectors, and practical freedom-to-operate contours at the claim-element level.
What does US 7,879,828 cover: composition elements and the full claim matrix?
Core claimed composition (independent claim 1):
A composition comprising:
- Active: tigecycline
- Excipient: lactose
- Acid: hydrochloric acid OR gentisic acid
- Molar ratio constraint: tigecycline:lactose between about 1:0.2 and about 1:5
- pH constraint (in solution): between about pH 3.0 and about pH 7.0
This structure is reinforced by dependent claim branching into:
- Lyophilized form (claim 2)
- Solid form (claims 3, 18-23)
- Tighter pH windows (claims 4, 5, 10, 11)
- Specific acid selection: HCl (claims 6-8, 12, 7-8 align to HCl)
- Tighter ratio window (claim 9, 13)
- Combination of tighter ratio + tighter pH (claims 12-17)
Claim elements that drive infringement and claim construction
The infringement-relevant “tripwires” in claim 1 are:
- Presence of lactose as a required component (not optional)
- Presence of one of two specific acids (HCl or gentisic acid)
- Quantified tigecycline:lactose molar ratio (1:0.2 to 1:5)
- Quantified solution pH window (3.0 to 7.0)
- Defined “pH of the composition in a solution”: pH is not the solid-state pH, it is measured after reconstitution/dissolution (or during a solution assay condition stated in the patent record; the claim language only requires that pH is “of the composition in a solution”)
Scope in plain terms
Within the literal claim, a product can look like:
- Tigecycline + lactose + acidified with HCl or gentisic acid
- Must fall within the specified ratio and solution pH ranges.
- Must be solid only if it asserts solid/lyophilized dependent claim sets; the independent claim 1 already covers “a composition” without specifying solid form.
How broad are the ratio and pH windows, and how do dependent claims narrow them?
Ratio window coverage (tigecycline:lactose)
- Claim 1: 1:0.2 to 1:5
- Claim 9 (tighter): 1:1.6 to 1:3.3
- Claim 12 mirrors claim 1 but is scoped to HCl specifically, and claim 13 mirrors claim 9 in that HCl context.
Practical implication: The dependent narrower ratio (1:1.6 to 1:3.3) is a subset; a formulation meeting claim 1 but outside claim 9 could still fall within claim 1.
pH window coverage
- Claim 1: pH 3.0 to 7.0
- Claim 4: pH 4.0 to 5.0
- Claim 5: pH 4.2 to 4.8
- Claim 10: pH 4.5 to 6.0
- Claim 11: pH 4.5 to 5.5
Subrange overlap map (key for design-arounds):
- Claim 5 (4.2–4.8) is contained within claim 4 (4.0–5.0)
- Claim 10 (4.5–6.0) overlaps claim 4 (4.0–5.0) and includes region above pH 5.0
- Claim 11 (4.5–5.5) overlaps both claim 10 and claim 4
Practical implication: If the product targets pH 3.0–4.0, it avoids claims 4/5/10/11 but still remains within claim 1. If it targets pH 5.5–7.0, it avoids claim 4/5/11 but may still be within claim 1 and could fall within claim 10 for 5.5–6.0. If it targets pH 4.2–4.8, it lands inside all the narrower pH claims.
Which acids are claimed, and what does that mean for formulation substitution?
Acid scope
- Claim 1: acid selected from hydrochloric acid and gentisic acid
- Claims 6-8: acid is hydrochloric acid
- Claim 12: expressly hydrochloric acid
- Claims 7-8 add HCl for the lyophilized and solid-form dependent branches.
Design-around vector at the acid-selection layer:
A formulation using neither HCl nor gentisic acid would not satisfy the acid element of claim 1. However, a product that uses HCl will fall into claim 12 plus potentially into claim 6-8, depending on form and pH/ratio.
Key point: The independent claim allows gentisic acid, so an attempt to substitute with an alternative “common acid” like citric or acetic acid would avoid literal coverage, while substitution with gentisic acid would still land within the claim.
Does the patent cover lyophilized and solid dosage forms, or only solutions?
US 7,879,828 includes explicit solid embodiments:
- Claim 2: composition of claim 1 where composition is lyophilized
- Claim 3: composition of claim 1 where composition is in solid form
- Claims 18-23: solid-form dependencies in the HCl + ratio + pH narrowed branches
Claim-level conclusion:
- The presence of pH is tied to the composition in a solution, not to a dry solid assay.
- The patent still asserts exclusive rights over solid (including lyophilized) compositions as delivery formats, provided the dissolved/reconstituted solution meets the ratio and pH constraints.
Where are the claim “fallbacks”: what additional limitations are stacked in dependent claims?
The dependent claims stack in an incremental way:
Independent claim 1 is broad across form, then dependent claims add:
- Lyophilized (claim 2)
- Solid form (claim 3)
- Tighter pH windows (claims 4-5, 10-11)
- Specific acid constraint to HCl (claims 6-8)
- Tighter ratio window (claim 9)
Claims 12-17 are a second independent-like branch framed as:
- Acid = hydrochloric acid (claim 12)
- Ratio window narrowed (claim 13)
- pH window tightened with multiple alternatives (claims 14-17)
- Solid-form locked (claims 18-23)
Fallback hierarchy (from a legal risk perspective):
If a competitor matches claim 12’s HCl constraint but misses one of the narrower pH windows, they may still face claim 12 if claim 12 itself remains satisfied (pH 3.0–7.0 in claim 12). If they match claim 1 acid selection (gentisic or HCl), they still meet the independent scaffold, unless they evade ratio or pH.
Infringement test: what must a product meet to land in each claim group?
Claim 1 infringement requires all of:
- Tigecycline present
- Lactose present
- Acid is either HCl or gentisic acid
- Ratio in range (1:0.2 to 1:5)
- Solution pH in range (3.0 to 7.0)
Claim 2 adds:
Claim 4 and claim 5 add:
- Solution pH in narrower windows (4.0–5.0; 4.2–4.8)
Claim 6-8 add:
Claim 9 adds:
- Ratio tightened (1:1.6–1:3.3)
Claim 10-11 add:
Claim 12-17 add:
- HCl fixed
- and select a ratio window and pH window depending on which dependent claim is asserted
Claims 18-23 add:
How strong is this claim set structurally: is it easy to design around or hard?
Hard to evade if your product stays within typical “acidified lyophilized” formulation space. The claimed pH span for independent claim 1 is broad (3.0–7.0), and the ratio span is also wide (1:0.2–1:5). If a company is using lactose and acidification with HCl or gentisic acid, the remaining degrees of freedom are mainly:
- moving tigecycline:lactose outside 1:0.2–1:5, or
- moving solution pH outside 3.0–7.0, or
- removing lactose, or
- changing the acid away from HCl and gentisic acid.
Easier to design around if you can change an essential excipient or acid:
- Removing lactose eliminates an express element.
- Using a non-HCl, non-gentisic acid changes the acid element.
- Operating at pH outside 3.0–7.0 eliminates the pH element.
How does US 7,879,828 likely sit inside the tigecycline formulation patent ecosystem?
Without the patent’s specification text, prosecution record, and the complete US family, a full landscape cannot be enumerated. Still, the claim content reveals the patent’s “technology focus”:
- stability and manufacturability of tigecycline via controlled excipient ratio and acidified pH for liquid-to-solid (including lyophilized) settings.
Landscape inference at the claim-scope level
Most tigecycline formulation portfolios tend to cluster around:
- solid-state forms (freeze-dried/lyophilized vs. other solids)
- buffer systems and acidifiers
- protective excipients (sugars like lactose or equivalents)
- reconstitution pH targets
US 7,879,828 sits specifically at the intersection of:
- lactose-based composition
- acidified solution pH windows
- defined molar ratio windows
- lyophilized/solid formats
What this implies for “adjacent” patents in the same category
Competitors’ risk typically comes from:
- broader excipient selection claims that still include lactose
- acid system claims that include HCl or gentisic acid
- pH-limited claims that overlap pH 3.0–7.0
- solid/lyophilized packaging that meets the same solution conditions upon reconstitution
What generic entry risks exist for formulations that match lactose + HCl/gentisic + broad pH?
Using the claim boundaries only, risk is highest when a generic or follow-on product:
- contains lactose
- uses HCl (or gentisic acid)
- reconstitutes to pH within 3.0–7.0
- uses a tigecycline:lactose molar ratio within 1:0.2–1:5
If those conditions hold, claim 1 is met regardless of whether the product is lyophilized or solid (unless the asserted claim is dependent). If the dosage form is lyophilized, claims 2 and the HCl-based solid subsets add further coverage.
Where the narrower subclaims matter
Narrow pH/ratio claims matter for:
- products that already avoid claim 1 by moving outside one element (e.g., pH near the extremes), but still accidentally fall into a narrowed subrange
- litigation that asserts narrower dependents as alternative theories if the accused product only partially matches
Timeline and regulatory exclusivity: not addressable from provided data
No Orange Book listing, approval date, patent-term schedule, pediatric exclusivity, orphan exclusivity, or FDA regulatory pathway details are provided. Without those, a timeline cannot be produced.
Key Takeaways
- US 7,879,828 claims a composition defined by five hard elements: tigecycline + lactose + HCl or gentisic acid + tigecycline:lactose molar ratio (1:0.2 to 1:5) + reconstituted solution pH (3.0 to 7.0).
- Dependent claims narrow to lyophilized and solid forms, and tighten to specific pH bands (notably 4.0–5.0 and 4.2–4.8) and a tighter ratio band (1:1.6 to 1:3.3).
- Design-around is most feasible at the element level: change acid away from HCl/gentisic, change excipient away from lactose, or operate outside the pH and/or ratio windows.
FAQs
-
If a formulation uses gentisic acid instead of hydrochloric acid, does it still risk claim 1 infringement?
Yes, claim 1 includes “acid selected from hydrochloric acid and gentisic acid.”
-
Does a product need to be lyophilized to infringe US 7,879,828?
No. Lyophilization is a limitation in dependent claim 2; claim 1 does not require lyophilization.
-
What single parameter change is most likely to fall outside claim 1 fastest: pH or tigecycline:lactose ratio?
Either can work. Claim 1 has wide windows on both, but moving either outside its range avoids the corresponding element.
-
Are the narrower pH claims (4.2–4.8) independent rights or subsets?
They are dependent limitations built on claim 1, so they are narrower subsets of the independent scope.
-
If an accused product meets ratio and pH but uses an acid other than HCl or gentisic acid, is claim 1 avoided?
Yes, because the acid is an express required element limited to HCl or gentisic acid.
References
- Provided claims text for US Patent 7,879,828 (user-supplied).
